Danaher Corp (DHR) delivered a solid finish to 2025, beating Wall Street's estimates on both the top and bottom lines. But investors seemed unimpressed, sending shares down more than 2% despite the life sciences giant's optimistic tone about gradual market recovery ahead.

The company reported fourth-quarter sales of $6.84 billion, up 4.5% year-over-year and topping the consensus estimate of $6.81 billion. Core revenue climbed 2.5%, landing right in line with management's earlier forecast of low single-digit growth. Adjusted earnings came in at $2.23 per share, comfortably ahead of the $2.15 consensus.

"We delivered a strong finish to the year with better-than-expected performance across our portfolio," said CEO Rainer Blair. "We were particularly encouraged by continued strength in our bioprocessing business, along with improved momentum in Diagnostics and Life Sciences. Our teams' disciplined execution also enabled us to exceed our fourth quarter margin, earnings, and cash flow expectations."

Breaking Down the Segments

Bioprocessing was the clear winner this quarter. Biotechnology sales jumped to $2.033 billion from $1.87 billion a year earlier, notching 6% core growth. That's a bright spot in what's been a challenging environment for the life sciences sector.

The Life Sciences segment showed more modest gains, with sales reaching $2.09 billion compared to $2.03 billion in the prior year. Core growth squeaked out at 0.5%, reflecting the ongoing sluggishness in research spending and biopharma funding.

Diagnostics picked up some momentum, with sales increasing from $2.64 billion to $2.72 billion and core growth of 2%. Cepheid's respiratory revenue hit around $500 million for the quarter, a meaningful contributor as seasonal illness testing remained steady.

Margin Beat and Cash Generation

Danaher delivered an adjusted operating profit margin of 28.3% in the fourth quarter, surpassing expectations of around 27%. The company also generated operating cash flow of $2.1 billion and adjusted free cash flow of $1.8 billion, demonstrating the operational efficiency that's become a hallmark of the Danaher Business System.

What's Ahead for 2026

"Looking ahead, we expect the gradual improvement in our end markets we saw through 2025 to continue, and we believe the combination of our differentiated portfolio, the power of the Danaher Business System, and the strength of our balance sheet positions Danaher for long-term value creation as we move into 2026 and beyond," Blair noted.

For fiscal 2026, Danaher expects adjusted earnings of $8.35 to $8.50 per share, essentially matching the consensus of $8.42. The company is forecasting core revenue growth between 3% and 6%, with some interesting segment-level dynamics:

• Bioprocessing should grow at a high single-digit rate, driven by consumables strength, though equipment demand remains flat.
• Discovery and Medical revenue is projected to be flat, consistent with broader Life Sciences trends.
• The Life Sciences outlook assumes only modest improvement in end-market conditions.
• Respiratory revenue is expected to hit approximately $1.8 billion, roughly matching 2025 levels.

First Quarter Guidance

For the first quarter of 2026, management expects core revenue growth in the low single digits, with end-market conditions largely mirroring what the company saw in Q4 2025. Cepheid's respiratory revenue should remain steady at around $500 million, down from approximately $625 million in the year-ago quarter. The company is targeting an adjusted operating margin of approximately 28.5%.

Despite the beat and the steady outlook, Danaher shares traded down 2.23% to $230.50 on Wednesday. Sometimes even a solid quarter isn't enough when investors are hungry for stronger growth signals.